Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' Equity

v3.21.1
Consolidated Statement of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscription Receivable [Member]
Stock Dividend Payable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2018 $ 552 $ 19,124,600 $ (1,800,000) $ (7,624,134) $ 9,701,018
Balance, shares at Dec. 31, 2018 5,525,128          
Conversion of Senior convertible debt for common stock and stock purchase warrants $ 2 258,928 258,930
Conversion of Senior convertible debt for common stock and stock purchase warrants, shares 18,107          
Payments made by investor for clinical trial costs 900,000 900,000
Pledged shares of common stock forfeited upon revised research funding commitment $ (5) (899,995) 900,000
Pledged shares of common stock forfeited upon revised research funding commitment, shares (56,640)          
Deemed stock dividend due to full ratchet anti-dilution adjustment (3) 3
Stock-based compensation 510,478 510,478
Stock-based compensation, shares          
Shares withheld to pay income tax on stock-based compensation          
Net loss (3,357,876) (3,357,876)
Balance at Dec. 31, 2019 $ 549 18,994,008 3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,595          
Conversion of Senior convertible debt for common stock and stock purchase warrants
Conversion of Senior convertible debt for common stock and stock purchase warrants, shares          
Payments made by investor for clinical trial costs
Pledged shares of common stock forfeited upon revised research funding commitment
Pledged shares of common stock forfeited upon revised research funding commitment, shares          
Deemed stock dividend due to full ratchet anti-dilution adjustment
Shares issued in connection with our 2020 offering, net of transaction costs of $2,099,363 $ 480 17,100,157 17,100,637
Shares issued in connection with our 2020 offering, net of transaction costs of $2,099,363, shares 4,800,000          
Shares issued in connection with license agreements $ 195 7,799,805 7,800,000
Shares issued in connection with license agreements, shares 1,950,000          
Shares issued due to full-ratchet anti-dilution adjustment $ 116 (116)
Shares issued due to full-ratchet anti-dilution adjustment, shares 1,156,487          
Conversion of LOC Agreement into shares of common stock $ 19 718,314 718,333
Conversion of LOC Agreement into shares of common stock, shares 199,537          
Conversion of 8% Senior Convertible Notes into shares of common stock $ 25 889,488 889,513
Conversion of 8% Senior Convertible Notes into shares of common stock, shares 247,088          
Stock dividend distributed due to full-ratchet anti-dilution adjustment $ 3 (3)
Stock dividend distributed due to full-ratchet anti-dilution adjustment, shares 28,971          
Fair value of warrants issued in the sale of our 2019 Senior Notes 197,403 197,403
Stock-based compensation $ 34 2,730,008 2,730,042
Stock-based compensation, shares 343,110          
Shares withheld to pay income tax on stock-based compensation $ (2) (95,210)   (95,212)
Shares withheld to pay income tax on stock-based compensation, shares (23,804)          
Net loss (14,413,788) (14,413,788)
Balance at Dec. 31, 2020 $ 1,419 $ 48,333,857 $ (25,395,798) $ 22,939,478
Balance, shares at Dec. 31, 2020 14,187,984